SCHEMBL23121669

SCHEMBL23121669

O=C1CCN(c2cccc(C(=O)N3CCC(OC4CCNCC4)CC3)c2)C(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 3/20 0.46
▸ CRBN Q96SW2 3/20 0.46
▸ GABRD O14764 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ GABRA2 P47869 1/20 0.41
▸ GABRB2 P47870 1/20 0.41
▸ GABRA4 P48169 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HCRTR1 O43613 1/20 0.39
▸ EGFR P00533 2/20 0.39
▸ L3MBTL3 Q96JM7 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ BCL9 O00512 1/20 0.38
▸ CTNNB1 P35222 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ MGLL Q99685 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23122759 0.99 DDB1 (0.46) DDB1CRBNGABRDGABRA1GABRB1
SCHEMBL28783614 0.91 DDB1 (0.47) DDB1CRBNALDH1A1TSHRHCRTR1
SCHEMBL23133973 0.87 DDB1 (0.44) DDB1CRBNALDH1A1TSHREGFR
SCHEMBL23134742 0.87 DDB1 (0.44) DDB1CRBNALDH1A1TSHREGFR
SCHEMBL23121717 0.87 DDB1 (0.40) DDB1CRBNGABRDGABRA1GABRB1
Hydrochloric Acid SCHEMBL23121758 0.86 DDB1 (0.40) DDB1CRBNALDH1A1TSHRHCRTR1
SCHEMBL25935495 0.86 DDB1 (0.56) DDB1CRBNGABRDGABRA1GABRB1
SCHEMBL23123218 0.85 CRBN (0.49) DDB1CRBN
SCHEMBL30009143 0.85 CRBN (0.49) DDB1CRBN
SCHEMBL27148853 0.83 CRBN (0.46) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-10-06 — — US disclosed
EP-4041724-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE Novartis AG (CH) 2022-08-17 — — EP disclosed
CN-114641473-A BRD9 bifunctional degradation agent and use method thereof 诺华股份有限公司 2022-06-17 — — CN disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 — — WO disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE BRD9, BRD2, BRD1 DDB1 1555/4885CRBN 850/4885GABRD 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback